Tumoral markers ( @entity10224 -- @entity478 ) in the screening of XXXX .

@entity43 @entity1 @entity478 @entity146 @entity5 @entity10224
@entity43 has high rate of mortality among @entity5 . Because of its @entity146 and low rate of 5 year survival of @entity1 treated, it is important to realise a screening program for its early diagnosis. Today, immunologic research is directed to the study of tumoral markers that allow us to detect the presence of still clinically silent @entity43 . Some tumoral markers such as @entity478 and @entity10224 are available for post-surgical monitoring of @entity1 treated for @entity43 . The Authors have carried out a study to evaluate the possibility of their use in the depistage of ovarian neoplastic pathology. A blood sample was taken for the evaluation of serum @entity478 and @entity10224 in a series of 520 @entity1 older than 45 years, who did not complain signs or symptoms of pelvic pathology. A pathologic value for @entity478 was considered higher than 7.3 ng/ml and for @entity10224 greater than 37 U/ml. For @entity478 2.5% (13 cases) presented pathologic values compared to 2.88% (15 cases) for @entity10224 . One third of cases (0.5%) with high levels of @entity478 had repeated blood samples. 3 of them had confirmed high levels of @entity478 but echotomography performed in these @entity1 was negative for pathologic ovarian masses. 15 @entity1 had @entity10224 high levels. 3 out of 15 cases repeated the blood sample that resulted normal. On 11 of these cases an echotomography was also performed that diagnosed a uterine myomatosis in 4 @entity1 .(ABSTRACT TRUNCATED AT 250 WORDS)
